Tat is considered as a target for the development of novel anti-AIDS therapies.
Tat biology has been the subject of several reviews (4) (5) (6) (7) . The aim of the present paper is to review recent studies examining how interference with HIV-Tat biology may be a key therapeutic strategy to cure AIDS.
The HIV-1 Tat gene encodes for a 86-101 amino acid polypeptide that acts as the main transactivating factor of HIV (6) . Tat protein can be actively released by HIVinfected cells (7) and is detected in the serum of HIV-infected individuals (8). Extracellular Tat is able to enter latently HIV-infected cells and activate the transcription of the viral genome. In AIDS patients, the reactivation of HIV by extracellular Tat may explain the burst of replication associated with early phases of HIV infection, where synchronized virion replication takes place (9). Moreover, extracellular Tat promotes HIV-1 coreceptors expression (10), thus inducing a self-perpetuating permissiveness for HIV-1 infection. Extracellular Tat also acts on different types of uninfected cells by interacting with several receptors including integrins α 5 β 1 , α v β 3 and α v β 5 ; the vascular endothelial growth factor (VEGF) receptors VEGFR1/Flt-1 and VEGFR2/KDR; and the chemokine receptors CCR2 and CCR3 and CD26 (also known as dipeptidyl peptidase IV) (7) . More recently, Tat has been shown to also bind the chemokine receptor CXCR-4 (11), the low density lipoprotein receptor-related protein (LPR) (12) and heparan sulfate proteoglycans (HSPGs) (13) .
Given the variety of receptors bound by extracellular Tat, it can be expected that a complex network of signal transduction pathways must be activated by the transactivating factor in target cells (7) . Also, LPR and HSPG receptors mediate the internalization of Tat inside the cell. As already mentioned, internalized Tat retains the capacity to transactivate viral and/or cellular genes.
Extracellular Tat exerts a variety of biological activities some of which have been tentatively associated with distinct AIDS-associated pathologies (Fig. 1 ). For example, Tat is considered a neurotoxin implicated in the pathogenesis of AIDS dementia (14) and also acts on different cells of immunity contributing to the immune suppression in AIDS patients (4, 7) . Tat appears to be responsible, at 
Introduction
The clinical features that characterize AIDS cannot be ascribed to the simple infection of CD4 + cells by HIV, especially when considering that only a small percentage of T cells are infected by the virus throughout the progression of the disease (1) . Accordingly, classical antiantiviral monotherapies have demonstrated very limited benefits. Also, AIDS-associated pathologies such as dementia, Kaposis sarcoma (KS) and the increased incidence of tumors cannot be explained merely by the death of HIV-infected cells. The complex pathogenesis of AIDS involves additional extracellular factors which are able to act on HIV uninfected cells. Several cytokines aberrantly produced during HIV infection may explain, at least in part, some of the pathological effects observed in AIDS patients (2) . In addition, viral proteins may act as extracellular toxins significantly contributing to some of the pathological events associated with AIDS (3) . Among these, the transactivating factor (Tat) of HIV-1 has been shown to be crucial for HIV replication and to be involved in the pathogenesis of AIDS-associated diseases. Thus, be completely eradicated, HAART must be administered chronically, increasing its cost and leading to the development of highly drug resistant HIV strains. Moreover, HAART is frequently discontinued by patients as a drug holiday or because of drug intolerance thus allowing for the reactivation of HIV-1 and progression of AIDS. Therefore, novel anti-AIDS therapies should control AIDS progression and cure associated pathologies rather than eradicate HIV itself. Moreover, the cost of anti-AIDS drugs must minimized due to the dramatic increase of AIDS infection in the third world (18, 19) .
Tat plays a pivotal role in HIV replication and in several AIDS-associated pathologies and is also implicated in the massive initial viral output that correlates with unfavorable prognosis and to the development of HIV mutants that overwhelm the immune system and/or vaccination (20) . Also, Tat is secreted and is characterized by a high amino acid conservation (20) . Interestingly, a stretch of repeated Arg and Lys residues (basic domain) occurs in the Tat protein and is implicated in several aspects of Tat biology. Indeed, it drives nuclear and nucleolar delivery of Tat, mediates the interaction of Tat with some cell surface receptors and nucleic acids and is required for some of the biological activities of extracellular Tat (21). The basic domain is a highly immunoreactive region and is well conserved among Tat proteins isolated from different HIV-1 strains (20, 22) . These characteristics make Tat a good candidate for the development of an anti-AIDS vaccine and/or drugs (20) .
When considering Tat as a target for drug/vaccine approaches, it should be keep in mind that it acts both as an intracellular transactivating factor and as an extracellular, pleiotropic cytokine. However, it is worth noting that extracellular Tat can be internalized by target cells where it retains its intracellular transactivating potential. These features help to identify different possible anti-Tat least in part, for the observed increased incidence of tumors in AIDS patients (4), as well. Also relevant to this point, extracellular Tat induces neovascularization (7) that is required for tumor growth and metastasis. Therefore, extracellular Tat has been implicated in the development of hypervascularized KS (7). Furthermore, extracellular Tat transactivates the genome of human herpes virus 8 (15) , hepatitis virus C (16) and human cytomegalovirus (17) , thus favoring secondary infections. And finally, extracellular Tat induces upregulation of a wide spectrum of cytokines, chemokines, growth factors and their receptors (4) . This suggests that a complex interplay may occur in which Tat-driven upregulation of cytokines amplifies the spectrum of the biological effects associated with the action of the transactivating factor.
Tat as a potential target for the treatment of AIDS
Many features make HIV peculiar among human viruses and HIV infection difficult to eradicate. The high levels of viremia found in the initial acute HIV infection quickly decline as the immune response develops, but latent infection persists throughout the long period of latency. Under the pressure of the immune response, the initial homogeneity of the virus is replaced by the rapid appearance of different viral strains. This represents the main obstacle to classical vaccine approaches to AIDS treatment. Indeed, antibodies directed toward HIV structural proteins cannot take into account the great epitope diversity existing among and within infected individuals. Thus, anti-AIDS therapies have been based mainly on inhibitors of HIV replication (highly active antiretroviral therapy [HAART] ) which have significantly decreased AIDS mortality in the U.S. However, because the virus latently resides in resting memory CD4 + cells and cannot is radically different from previous ones. This new vaccine would be similar to toxoid vaccines for diphtheria or tetanus in that it could be directed against a viral product implicated in the pathogenesis of the disease rather than against the virion itself. Several considerations point to Tat as a good candidate for an anti-AIDS vaccine. First, HIV infection does lead to an immune response. Among the viral proteins, reaction against Tat is the quickest both in primates (25) and humans (26, 27). High levels of humoral and cellmediated immune response against Tat correlate with better prognosis (3, (26) (27) (28) (29) (30) (36) . The rationale for the use of native Tat is based on the possibility that the structural modifications introduced in a toxoid would destroy the main immunogenic epitopes of the protein. On the other hand, the side effects caused by immunization with gp120 in humans (24) suggest caution when using native, bioactive HIV proteins. strategies, such as the inhibition of extracellular Tat interaction with target cells and/or its intracellular uptake, the intracellular blockade of Tat production and release by HIV-infected cells and the disruption of Tat interaction with its intracellular cofactors or with TAR RNA (Fig. 2) . On this basis, extracellular and intracellular Tat antagonists will be discussed separately.
Extracellular Tat antagonists
Theoretically, the biological activity of extracellular Tat can be neutralized by anti-Tat antibodies, Tat-binding compounds, Tat receptor antagonists or inhibitors of Tat activated signal transduction pathways (Fig. 2 ).
Tat as a vaccine
Vaccination against HIV is a major goal for the treatment of AIDS because it would provide both prophylactic and therapeutic benefits at costs significantly lower than those of HAART therapies.
More than 60 phase I/II trials of up to 30 candidate AIDS vaccines have been conducted thus far (23). Accordingly, up to 600 articles have been published about AIDS vaccines, erroneously suggesting that this kind of cure is at hand. Unfortunately, this may not be true. Indeed, the most promising AIDS vaccine, one directed against the gp120 protein, was recently demonstrated to be ineffective and harmful to humans (24). For many years Tat was not considered a candidate target for an AIDS vaccine because of its intracellular localization. However, the discovery of an extracellular role for Tat would enable use of a strategy for AIDS vaccination that extracellular Tat and to inhibit its transactivating activity (55). Pentosan polysulfate (PPS) interacts with Tat protein with a 10-fold higher affinity than that of heparin. Accordingly, PPS is highly effective in preventing the interaction of Tat with target cells and in inhibiting the LTR-transactivating and mitogenic activity of Tat in vitro. Also, PPS inhibits Tat-induced neovascularization in vivo (56).
Recently, it was shown that it is possible to produce biotechnological heparin-like molecules by controlled sulfation of the Escherichia coli K5 polysaccharide (57). These products have been demonstrated to interact with FGF2 and to inhibit its biological activity in vitro and in vivo (58). Experiments performed in our laboratory have shown that an appropriate sulfation confers Tat binding capacity and specific Tat antagonist activity to K5 polysaccharide (Urbinati et al., manuscript in preparation).
Inhibitors of extracellular Tat receptors
Because Tat can interact with different cell surface receptors, they might be considered targets for Tat antagonists under selected conditions when the cytokine-like action of Tat plays a pathogenic role.
Anti-KDR antibodies inhibit Tat-driven chemotactic migration of endothelial cells in vitro and Tat-induced neovascularization in vivo (59). Accordingly, anti-KDR antibodies inhibit the mitogenic activity of extracellular Tat in epithelial cells (Urbinati C., unpublished observations).
Arg-Gly-Asp (RGD)-containing peptides are well known antagonists of integrin receptors (60). Accordingly, we have observed that linear RGD-containing peptides inhibit integrin-mediated cell adhesion to immobilized Tat. Interestingly, cyclization of RGD-containing peptides increases their Tat inhibitory potency (Urbinati et al., manuscript in preparation). However, RGD-containing peptides may exhibit aspecific inhibition that can interfere with the function of platelet-associated integrin alpha IIb beta 3 that is required for a correct coagulation process. Based on this, an RGD-peptidomimetic compound (SCH-221153) has been developed that selectively binds to α v β 3 and α v β 5 but not to α IIb β 3 (60). Preliminary experiments have shown that SCH-221153 exerts significant Tat antagonist activity in vitro (Urbinati et al., manuscript in preparation).
Inhibitors of Tat-activated intracellular second messengers
The interaction of extracellular Tat with cell membrane receptors activates a variety of intracellular signaling pathways and some second messengers appear to be activated by intracellular Tat.
We have observed that the mitogenic activity exerted by extracellular Tat in epithelial cells is inhibited by the tyrosine phosphorylation inhibitor tyrphostin, the protein Le Buanec et al. (37) developed a Tat toxoid that was demonstrated to be safe in mice, seronegative humans and immunocompromised HIV-1 infected patients (38). Subsequent studies with macaques immunized with the Tat toxoid and challenged with SHIV-89.6P demonstrated an attenuation of SHIV replication and disease but no protection against infection (37).
Novel approaches to the preparation of a Tat vaccine can be forseen. Immunogenic Tat sequences that overlap functional domains of Tat have been identified which can be exploited to design safe and efficient Tat vaccines (40, 41). These proteins elicit specific cellular or humoral responses in animals (42-44) and also minimize chronic plasma viremia in rhesus macaques infected with SHIV (45). Alternatively, immunization with cDNA encoding for Tat mutants has been shown to induce a humoral and cellular response against wild-type Tat (35, 46).
Despite its potential therapeutical implications, a Tat vaccine might not be sufficient to cure AIDS. More likely, Tat should be considered as a constituent of a composite vaccine (34). Indeed, vaccination with cDNAs encoding for Tat and other HIV proteins are under study (46-50).
Extracellular Tat-binding antagonists
The demonstration that heparin binds Tat (51) and that HSPGs act as Tat receptors (13) suggests that polyanionic heparin-like compounds may be used to sequester extracellular Tat, thus inhibiting cell interaction and biological effects. Indeed, the polysulfonated suramin acts as an extracellular Tat antagonist in different experimental models (21, 51, 52). However, its toxicity and lack of specificity represent serious limitations for the use of suramin as an anti-Tat drug. To overcome these limitations, a series of polysulfonated distamycine derivatives mimicking suramin were tested for Tat antagonist activity. These compounds compete with heparin/HSPGs for the binding to Tat (21). They inhibit the mitogenic and HIV-LTR-transactivating activity of Tat in vitro (21, 53) and its angiogenic, tumorigenic and metastatic potential in vivo (53, 54). Interestingly, distamycine derivatives retain their inhibitory activity when delivered to target cells by lipofection (53).
Two of the distamycin derivatives tested (PNU-151779 and PNU-157666) inhibited the LTR-transactivating activity and mitogenic capacity of extracellular Tat with a potency significantly higher than that of suramin and comparable to that of heparin (21). Interestingly, it is possible to dissociate the Tat antagonist activity of distamycin derivatives from their FGF2-antagonist activity by modification of their chemical structure (M. Rusnati, unpublished observations). These findings suggest that appropriate modifications in the backbone structure or in the distribution of the sulfonated groups of distamycine derivatives can lead to compounds with increased Tat antagonist potency and/or specificity.
Dextrin-2-sulphate (D2S) represents another polyanionic compound that has been demonstrated to bind lymphocytes and monocytes (71, 72). This inhibition can also be obtained in the presence of high multiplicity infections and inflammatory cytokines (73), an experimental condition that more closely resembles HIV infection in human patients. Accordingly, rhesus macaques infused with autologous lymphocytes engineered with antisense anti-tat gene and challenged with SIV showed a reduction in viral load, a sustained number of CD4+ cells and a decrease in lymph node disruption (74).
Ribozymes are metalloenzymes that retain the properties of an antisense RNA with the additional capacity of catalytic cleavage of specific RNA sequences (75) . Ribozymes directed against tat mRNA and expressed in target cells by plasmid transfection or retroviral infection effectively inhibit HIV replication (76) (77) (78) (79) (80) . Ribozymes were also shown to exert their Tat inhibitory effect on primary drug-resistant HIV strains with no mutations or loss of sensitivity to the ribozyme observed in a series of HIV passages in ribozyme-expressing cells (81) .
Finally, novel chimeric ribozymes have been developed that contain the target hybridizing arms in the form of DNA instead of RNA. DNA enzymes may be endowed with higher stability and a longer half-life in plasma with respect to the classical RNA-based ribozyme (82, 83) .
Also relevant to anti-tat gene therapy is the fact that hematopoietic stem cells, as opposed to circulating cells, can be transfected with anti-HIV genes without altering their differentiation (79, (84) (85) (86) . Theoretically, this may lead to the reconstitution of immune function in AIDS patients. Also, anti-HIV genes can be engineered under the control of Tat-dependent HIV-LTR promoter to drive their expression only in HIV-infected cells (73).
Anti-TAR antisense, decoy and antagonists
Tat stimulates HIV-1 transcription elongation by interacting with a stem-loop RNA element (TAR) formed at the extreme 5 end of all viral transcripts (6) . Thus, the Tat-TAR complex is considered an important target for anti-HIV strategies. Specific antisense oligonucleotides kinase C (PKC) inhibitor GF-109203X and the mitogen activated kinase (MAPK) p38 inhibitor SB-203580, but not by the phosphatidyl-inositol 3 kinase inhibitor LY-294002 (Rusnati et al., unpublished data). Accordingly, the PKC inhibitors curcumin (61) and staurosporine (62) inhibit the transactivating activity of Tat.
The MAPK ERK 1/2 is activated by extracellular Tat in many different cell types and may be located at the convergence of the signal transduction pathways activated by the interaction of Tat with KDR and integrins (63). In microglia, 17β-estradiol suppresses Tat-induced MAPK activation and consequent phagocytosis and superoxide/TNF-α release (64). In addition, the specific ERK 1/2 inhibitors PD-098059 and U-0126 effectively inhibit ERK 1/2 phosphorylation in endothelial (63) and epithelial cells (Rusnati et al., unpublished observations). They also inhibit the mitogenic activity of Tat in cultured epithelial cells (Rusnati et al., unpublished observations) but have no effect on Tat-induced neovascularization in vivo (63).
Arachidonic acid metabolism can be activated by Tat and quinacrine and chloroquine inhibit the LTR-transactivating activity of Tat (62). Tat also induces the production of phosphatidic acids. The specific inhibitor CT-2576 prevents the transactivating activity exerted by Tat in epithelial cells and HIV replication in promonocytic cells (65).
Diazepam has been shown to inhibit Tat-induced migration of human microglia by blocking Tat-induced Ca 2+ mobilization (66). Tat activation of the intracellular second messenger NF-κB is required for the transcription of the viral genome. Transdominant mutants of IκB α (an inhibitor of NF-κB) inhibit the transactivating activity of Tat and HIV replication when transfected in target cells (67). Also, natural molecules such as interleukin 16 (68) and nitric oxide (69) inhibit Tat-induced NF-κB activation.
In conclusion, specific inhibitors of several second messengers can be used to inhibit different biological activities of Tat. In addition to the possibility of identifying effective Tat antagonists, these studies may help to elucidate the signal transduction pathways responsible for the biological effects of extracellular Tat in target cells.
Intracellular Tat antagonists
Long before Tat was demonstrated to be secreted by HIV-infected cells, intracellular Tat was considered a target for anti-HIV therapies. Accordingly, several drugs and gene therapies aimed at blocking the biological activity of intracellular Tat have been described (Fig. 3) . mC2p, a pseudo-substrate for Cdk7 (108) , effectively block the transactivating activity of Tat and HIV replication in vitro.
Anti-tat antisense
Another intracellular Tat cofactor is the transcription factor Sp1 (5, 6). Sp3, an homolog of Sp1, represses Tatmediated transactivation when overexpressed in target cells. Sp3 acts by competing with Sp1 for interaction with the specific DNA-binding sequence (109) . Accordingly, the plant lignan 3-O-methyl nordihydroguaiaretic acid inhibits Tat-dependent transactivation in vitro by binding to Sp1 sites (110) .
Intracellular Tat antagonists with unknown mechanisms of action
Other synthetic compounds have been shown to act as Tat antagonists by inhibiting HIV replication even though their mechanism of action has not been fully elucidated. Among them, the benzodiazepine derivatives Ro 5-3335 and Ro 24-7429 were found to exert an inhibitory activity on several HIV strains in different HIV-infected cell types without causing emergence of drug-resistant HIV strains (111) (112) (113) (114) . Unfortunately, a randomized trial failed to show significant antiviral activity of Ro 24-7429 in AIDS patients (115) . This lack of effect may be due to the fact that benzodiazepines are ineffective on chronically infected monocytes (116) .
In the search for effective HIV-1 transcription inhibitors, Baba et al. identified a series of Tat antagonists including the 2-glycineamide-5-chlorophenyl 2-pyrryl ketone (117), the fluoroquinoline derivatives K-37 (118) and K-38 (119) and a novel substance produced by Streptomyces named EM-2487 (120) that inhibits HIV replication in acutely or chronically HIV-infected cells.
In addition, glucocorticoids (121), D-penicillamine and its derivatives (122, 123) , the topoisomerase I inhibitor camptothecin (124), the TNF-α release antagonist calventol (125) and keto/enol epoxy steroids (126) have been shown to inhibit the transactivating activity of Tat. Finally, β-interferon plus 13-cis-retinoic acid inhibit neovascularization induced by Tat in vivo, suggesting that this combination may have possible therapeutic implications in epidemic KS (127) .
Tat antagonists: the multitarget hypothesis
Up to 300 papers have been published to date addressing the possibility of blocking extracellular/intracellular Tat. Most of these studies, however, are limited to in vitro experiments. Only a few Tat antagonists were also effective in vivo and only one compound was tested in a clinical trial with poor results (115) . This lack of success may be due to the diverse features and mechanisms of action of Tat. Indeed, the blocking of Tat-TAR interaction may inhibit HIV replication but be ineffective against the pathological effects of extracellular Tat. In turn, extracellular Tat antagonists may not be able to access the complementary to the TAR apical stem-loop block Tat binding in vitro (87, 88) . Accordingly, infection of target cells with retroviral vectors carrying antisense-TAR inhibits the transactivating activity of Tat (73, 89). Inhibition of Tat-TAR interaction can also be achieved by means of a TAR RNA decoy that blocks the binding of Tat to the authentic TAR region. Indeed, when expressed in target cells, the TAR decoy significantly reduces HIV infection (89-91). It has been proposed that, after proper structural modifications, TAR decoys may be administered exogenously to target cells (92), also with the aim of targeting extracellular Tat.
Tat-TAR interaction can also be prevented by means of transdominant Tat TAR can also be targeted by chemical compounds such as the bisenzimidazole Hoechst-33258 (100), aromatic polyamidines (101) and tetrahydropyrimidine derivatives (102).
Anti-Tat intracellular intrabodies
Intracellular antibodies (intrabodies) can bind and inactivate intracellular antigens when expressed intracellularly in transfected cells. Marasco et al. (103) demonstrated that the expression of anti-Tat intrabodies in HIVinfected cells exhibits different HIV antagonist effects and that the structure of anti-Tat intrabodies can be genetically manipulated to increase their Tat antagonist activity (86, (103) (104) (105) .
Inhibitors of intracellular Tat cofactors
Several intracellular cofactors are required for the nuclear delivery of Tat protein and for its interaction with TAR-RNA (5, 6). Friedler et al. (106) developed a cyclic peptidomimetic compound that functionally mimics the basic domain of Tat. This compound blocks the interaction of intracellular Tat with importin-β and its nuclear accumulation. The effect is specific since the peptidomimetic does not influence the nuclear delivery of other nuclear proteins. P-TEFb is an intracellular complex composed of cyclin-dependent kinase (Cdk) 9 and cyclin T1. Tat-PTEFb interaction is required for the transactivation of the HIV promoter (5). Flavopiridol, a Cdk inhibitor (107) , and to cell surface (55) by binding to CD4 but not to gp120 (135) . Distamycine derivatives prevent HIV-1-induced cell killing (136) by inhibiting HIV-1 reverse transcriptase (137) and integrase (138) . They also downregulate chemokine receptors that act as HIV-1 coreceptors (139) and may also alter CD4 expression (140) .
Given these characteristics, these compounds should be considered only prototypes of multitargeting HIV antagonists since further development requires knowledge of the molecular basis of their interactions with HIVrelated proteins. Interestingly, both Tat and gp120 contain a stretch of positively charged amino acids that mediates their interaction with polyanionic molecules (21, 141). On the other hand, specific patterns of sulfated/sulfonated groups within polyanionic compounds determine the specificity of the binding to the different proteins (142) . It is conceivable that the identification of the structural features of polyanionic compounds required for Tat and/or gp120 binding will bring new insights to the design of efficient multitarget anti-HIV drugs. In this regard, a positive correlation exists between Tat antagonists and anti-HIV-1 activities of distamycin derivatives (Fig. 5) . Thus, it is possible that the multitarget effects of polyanionic compounds can be effectively investigated and possibly enhanced by modification of chemical structures.
Other compounds have been found to interfere with different aspects of HIV biology. The cell permeable peptidomimetic compound described by Friedler et al. (106) inhibits nuclear import of Tat and rev-RNA interaction simultaneously. The peptidoid CGP-64222 inhibits both Tat-TAR and HIV-CXC-4 interactions (143) . Similarly, the oligocationic peptide ALX40-4C inhibits both Tat-TAR interaction and HIV adsorption to target cells (144) . transactivating factor inside HIV-infected cells. Finally, drugs that efficiently block extracellular and/or intracellular Tat may not reach the central nervous system, thus being ineffective on microglia-released Tat and related AIDS dementia. An efficient anti-Tat therapy must incorporate all these aspects and, at least in theory, overcome the abovementioned obstacles. For instance, cell permeable cyclic peptides endowed with Tat antagonist activity have been described (106) . Tat-binding polyanionic compounds have been shown to block intracellular Tat once encapsulated in liposomes (53). Finally, the Tat antagonists diazepam and Ro 5-4864, readily cross the bloodbrain barrier (66).
In some AIDS-associated diseases Tat acts via or synergistically with other growth factors/cytokines, thus making it difficult to inhibit these pathological processes with specific Tat inhibitors. Tat mimics heparin-binding angiogenic growth factors like VEGF and FGF2. They share structural features, receptors and/or signal transduction pathways. On the other hand, VEGF and FGF2 cooperate with Tat during the pathogenesis of AIDSassociated KS (128, 129 Multitarget activity can also be directed to Tat and other HIV proteins. Indeed, some of the polyanionic Tat antagonists described in this review have been shown to also interact with different HIV proteins interfering with various aspects of the viral cycle (Fig. 4) .
Heparin disrupts the CD4-gp120 complex by binding to both proteins (130, 131) . PPS prevents HIV-1 replication (132) and sincitium formation (133) by inhibiting reverse transcriptase (134) and by binding to gp120 but not to CD4 (131) . In contrast, D2S inhibits HIV adsorption AIDS has long been treated as a classic infectious disease with therapies aimed at eradicating its etiological agent. It is now clear that this strategy is not successful and that an effective anti-AIDS therapy will require a multitargeted approach in which classic antiviral drugs and protease inhibitors are combined with novel extracellular Tat antagonists. This approach should prevent the development of drug-resistant HIV strains, decrease the dosage and related toxicity of each single drug and lead to a cure for AIDS-associated pathologies.
Compounds such as the diphenylfuran derivatives prevent Tat-TAR interaction and exert antibiotic activity against Pneumocystis carinii, one the major causes of mortality in AIDS patients (145) . The antibiotics neamin, neomycin and their derivatives also block TAR-Tat interaction and may simultaneously prevent secondary infections in HIV-infected individuals (144, 146) .
Purine nucleoside analogs such as 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (147) and carbocyclic adenosine analogs (148, 149) inhibit the transactivating activity of Tat and are expected to also elicit antiviral activity.
It has been hypothesized that an anti-HIV multitargeted effect can be achieved with combinations of drugs. Hsu et al. (114) suggested using the Tat antagonist Ro 24-7429 in combination with classic reverse transcriptase and/or proteases inhibitors to reduce new infections and viral chronicity. In fact, the anti-HIV effects of the compound were increased when it was combined with the NF-κB specific inhibitor, pentoxifylline (150) .
A multitarget approach to block intracellular Tat has also been developed that involves anti-tat antisenses coupled to TAR antisense which results in increased therapeutic efficacy (89, 73, 151, 152) . Transdominant Tat and Rev proteins transfected simultaneously into target cells exert an anti-HIV effect that is greater than that obtained with the transdominant proteins used alone (93). An anti-CCR5 ribozyme confers resistance to viral infection, but its efficiency is increased when used in combination with an anti-tat-rev ribozyme (153) . A double hammerhead ribozyme targeted to cleave both tat and rev transcripts has been cominbed with a rev decoy and a rev transdominant mutant resulting in better inhibition of HIV replication (85) . Anti-Tat intrabodies have been successfully used in combination with anti-gp120 intrabodies (154) or with NF-κB antagonists (155) .
Conclusions
Tat can be considered a target for the development of anti-AIDS therapies. Because it was believed to be the main HIV transactivator with an intracellular mechanism of action, initial efforts focused on the development and optimization of anti-tat gene therapies.
In the early 1990s, the discovery that Tat was present in the serum of HIV-infected individuals triggered a series of studies aimed at preparation of a Tat vaccine. The preliminary results are controversial and previous experience with vaccination against structural proteins of HIV suggest that caution should be used. In addition to vaccination, some recent papers discussed the possibility of designing and producing synthetic compounds that inhibit either the interaction of extracellular Tat with target uninfected cells or extracellular Tat-generated signal transduction. These recent developments have increased the therapeutic options available for the treatment of AIDS and its related pathologies. 
